Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $568.53M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.88M
Average 2.56M
Returns on capital
Annexon, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-97.7%
avg -47.5%
ROIC
-91.0%
avg -93.9%
ROA
-74.5%
avg -69.3%
Analysis
ROA is currently the strongest return metric at -74.5% versus its period average of -69.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Douglas Love | Chief Executive Officer, President & Director | USD 1.06M | 58 | 390.48K | 0.33% |
Dean R. Artis | Chief Scientific Officer & Executive Vice President | USD 797.38K | 65 | — | — |
Ted Yednock | Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board | USD 737.79K | 68 | 0 | <0.01% |
Jamie Dananberg | Executive Vice President & Chief Medical Officer | USD 715.23K | 68 | 123.58K | 0.10% |
Jennifer Lew | Executive Vice President, Chief Financial Officer & Corporate Secretary | USD 700.02K | 53 | 170.70K | 0.14% |
Michael Overdorf | Executive Vice President & Chief Business Officer | USD 580.47K | 55 | 182.63K | 0.15% |
Henk-Andre Kroon | Senior Vice President of Translational Medicine | — | — | — | — |
Shikhar Agarwal | Senior Vice President & Head of Commercial | — | — | — | — |
Linda A. Fitzpatrick | Chief Human Resources Officer | — | 69 | — | — |
Sunil Mehta | Senior Vice President of Medical Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 24, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$10.90M
Sells
10
$313,427.80
Net Transaction Value
+$10.58M
Net buying
Most Active
Satter Muneer A
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 24, 26Sep 24, 2026 | Love Douglas Direct | Buy | $99.8K$99,828.95 |
| May 28, 26May 28, 2026 | Satter Muneer A Indirect | Buy | $3.3M$3,319,018.77 |
| May 11, 26May 11, 2026 | Carson William H. Direct | Buy | $46.2K$46,240.00 |
| Apr 10, 26Apr 10, 2026 | Carson William H. Direct | Buy | $49.6K$49,600.00 |
| Mar 10, 26Mar 10, 2026 | Carson William H. Direct | Buy | $45.4K$45,360.00 |
| Mar 2, 26Mar 2, 2026 | Dananberg Jamie Direct | Sell | $31.6K$31,602.60 |
| Mar 2, 26Mar 2, 2026 | Overdorf Michael Direct | Sell | $23.5K$23,517.38 |
| Mar 2, 26Mar 2, 2026 | Yednock Ted Direct | Sell | $30.2K$30,167.72 |
| Mar 2, 26Mar 2, 2026 | ARTIS DEAN RICHARD Direct | Sell | $32K$32,004.42 |
| Mar 2, 26Mar 2, 2026 | Lew Jennifer Direct | Sell | $30.2K$30,162.30 |
1–10 of 22
Summary
Insiders reported 12 buys worth $10.90M and 10 sells worth $313,427.80 over the last 12 months. That adds up to net buying of $10.58M. Satter Muneer A was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Annexon, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ANNX's management, answered from reported figures.
Who manages ANNX?
Annexon, Inc. (ANNX) lists 10 active executives. The top listed executive is Jamie Dananberg, Executive Vice President & Chief Medical Officer.
Are ANNX insiders buying or selling?
Recent insider activity shows net buying of $72.72M.
Continue the stock analysis
Jump to another research area for this company.